Objective-To identify circulating microRNAs that are differentially expressed in severe coronary heart disease with well or poorly developed collateral arteries and to investigate their mechanisms of action in vivo and in vitro. Approach and Results-In our study, we identified a circulating microRNA, miR-15b-5p, with low expression that, nevertheless, characterized patients with sufficient coronary collateral artery function. Moreover, in murine hindlimb ischemia model, in situ hybridization identified that miR-15b-5p was specifically expressed in vascular endothelial cells of adductors in sham group and was remarkably downregulated after femoral artery ligation. Overexpressed miR-15b-5p significantly inhibited arteriogenesis and angiogenesis in mice. In vitro, both under basal and vascular endothelial growth factor stimulation, loss-of-function or gain-of-function studies suggested that miR-15b-5p significantly promoted or depressed the migration and proliferation of endothelial cells. We identified AKT3 (protein kinase B-3) as a direct target of miR-15b-5p. Interestingly, AKT3 deficiency by injection with Chol-AKT3-siRNA obviously suppressed arteriogenesis and the recovery of blood perfusion after femoral ligation in mice. Conclusions-These results indicate that circulating miR-15b-5p is a suitable biomarker for discriminating between patients with well-developed or poorly developed collaterals. Moreover, miR-15b-5p is a key regulator of arteriogenesis and angiogenesis, which may represent a potential therapeutic target for ischemic disease. Visual Overview-An online visual overview is available for this article. Correspondence to Guo-Gang Zhang, Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Xiangya Rd 87, Changsha, China, 410008. E-mail xyzgg2006@sina.com; or Yong-Ping Bai, Department of Geriatric Medicine, Xiangya Hospital, Central South University, Xiangya Rd 87, Changsha, China, 410008. E-mail baiyongping200613@163.com
A rteriogenesis, the basic process of coronary collateral formation, during which preexisting small arterioles are remodeled into large collateral arteries to divert blood flow around stenotic lesions, happens upstream of the ischemic area and is triggered by increasing fluid shear stress, rather than ischemia. Shear stress sensed by endothelial cells (ECs) triggers an inflammatory response that leads to a complex set of events involving interactions among various cell types and signaling circuits. 1 Angiogenesis is driven exclusively by ischemia. Ischemia induces neighboring ECs to form sprouts toward the ischemic area by upregulating proangiogenic growth factors. 2 Therefore, arteriogenesis and angiogenesis are both highly multifactorial processes.
Although interventional therapy and bypass surgery are effective treatments for patients with coronary heart disease, these procedures are not indicated for some patients and are associated with a high postoperative restenosis rate. 3 Welldeveloped collateral circulation and angiogenesis are crucial for improving the symptoms and prognosis of coronary heart disease patients. In addition, because the clinical trails on therapy of ischemic disease at present merely focus on one single factor, such as vascular endothelial growth factor (VEGF), which may lead to neoplastigenic side effect, 4 there is a demand in deliberating the master switches to modulate both arteriogenesis and angiogenesis.
MicroRNAs (miRNAs) are a class of small (≈22 nucleotides) single-stranded noncoding RNAs found in diverse organisms that downregulate the expression of target genes by either mRNA degradation or translational inhibition. 5 Each miRNA has multitarget genes, which means 1 single miRNA inhibition may affect the multifactorial physiological processes. Recently, several miRNAs have been found to be involved in the angiogenesis. 6 MiR-15b-5p reduced angiogenesis via NRP-2 (neuropilin 2) and MMP-3 (matrix metalloproteinase-3) by in vitro tube formation assay. 7 Subintestinal vessel formation was significantly suppressed by miR-15b-5p overexpression in zebra fish embryos. 8 MiR-145 restored the contractile vascular smooth muscle phenotype and coronary collateral growth in metabolic syndrome rats (JCR rats). 9 However, most of these miRNAs were identified in in vitro or animal studies rather than in human subjects.
In the present study, we screened circulating miRNAs in human subjects using high-throughput sequencing, and the data suggested that the patients with sufficient coronary collateral artery function could be characterized by low expression of miR-15b-5p. Moreover, we found that miR-15b-5p was highly expressed in EC layer under nonischemic condition, but downregulated in EC layer of collaterals in murine hindlimb ischemia model. We demonstrated that the overexpression of miR-15b-5p attenuated the functional recovery of limb ischemia after femoral ligation by inhibiting both arteriogenesis and angiogenesis. Mechanistically, we validated the miR-15b-5p effects on ECs and found its direct target in vitro. Interestingly, AKT3 (protein kinase B), a target of miR-15b-5p, exhibited a multifunction on arteriogenesis and angiogenesis in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Circulating miR-15b-5p Correlates With Insufficient Coronary Collateral Artery Function in the Patients of Coronary Artery Disease
Based on the Rentrop scoring system, all patients in a highly selected criterion with triple vessel disease or left main coronary artery disease were divided into 2 groups: poor coronary collateral circulation (CCC; grades 0 and 1) and good CCC (grades 2 and 3). As shown in Figure 1A and 1B, the expression profiles of 1457 miRNAs in plasma were compared between 5 patients with poor CCC and 5 patients with good CCC. A heat map displays the top 18 dysregulated miRNAs (differential expression ≥2-fold). Among them, significantly greater expression of hsa-miR-126-3p, hsa-miR-15b-5p, and hsa-miR-92a-3p was exhibited in the plasma of patients with poor CCC compared with those with good CCC (P values of 0.040, 0.043, and 0.040, respectively).
Based on the miRNA profiling data from high-throughput sequencing, we further validated the expression of miR-126-3p, miR-15b-5p, and miR-92a-3p in an independent cohort of 20 patients with poor CCC and 18 patients with good CCC (see Table I in the online-only Data Supplement for patient characteristics) using real-time reverse transcription polymerase chain reaction ( Figure 1C ). Using cel-miR-238-3p to normalize the miRNA expression levels, we confirmed significantly greater miR-15b-5p (P<0.05) and miR-126-3p (P<0.01) expression in patients with poor CCC. However, no significant association was found between miR-92a-3p (P>0.05) and CCC. To further determine miR-15b-5p as a biomarker for CCC, we simultaneously detected miR-15b-5p expression in 18 age-matched healthy controls; our data indicated that plasma miR-15b-5p expression in both good CCC and poor CCC significantly declined when compared with those in healthy controls (P<0.01, both; Figure I in the online-only Data Supplement).
To clarify the diagnostic value of these 3 differentially expressed miRNAs in plasma, receiver operating characteristic curve analysis was conducted. As shown in Figure 1D and in Table II in the online-only Data Supplement, circulating miR15b-5p and miR-126-3p were identified as significant predictors of collateral capacity between patients with good CCC and poor CCC (P<0.05; area under the curve (AUC) of 0.69 and 0.75, respectively). However, no similarly predictive role for miR-92a-3p was observed. A multivariate logistic regression model (Table IV in the online-only Data Supplement) with age, sex, high-density lipoprotein, and smoking further confirmed that miR-15b-5p and miR-126-3p had diagnostic significance (P<0.01; AUC of 0.83 and 0.82, respectively) in CCC. Interestingly, after correcting the influence of age and sex, high-density lipoprotein, and smoking, circulating miR-92a-3p was also found to be characteristic of patients with insufficient coronary collateral artery function (P<0.01; AUC of 0.82). As miR-126 was reported as in several previous studies of arteriogenesis and angiogenesis, 10, 11 we further verified the diagnostic power of miR-15b in good CCC and poor CCC compared with those in the healthy controls, respectively. Figure II and Table  III in the online-only Data Supplement indicated that miR15b-5p distinguished good CCC from healthy controls with AUC of 0.88 (P<0.01); the predictive power of miR-15b-5p was also high within the poor CCC when comparing with healthy controls (P<0.01; AUC of 0.76). Taken together, these data suggested that circulating miR-15b-5p might act as a biomarker for discriminating patients with good or poor CCC.
To explore the probable functions and downstream networks of these 3 miRNAs, 2218 target genes were predicted by a Targetscan site. Gene ontology and pathway analysis indicated that PI3K (phosphoinositol-3-kinase)-AKT signaling related to cell proliferation may be the downstream pathway of the above-mentioned miRNAs involved in collateral artery formation ( Figure 1E ).
MiR-15b-5p Expression in Murine Hindlimb Model
To further analyze the source of circulating miR-15b-5p, a mouse hindlimb ischemia model was constructed. Consistent with previous studies, 12 the blood flow in hindlimbs measured by laser speckle after ligation began to recover obviously on day 7 and recovered to almost normal on day 21 (Figure 2A was significantly reduced in adductors after ischemic injury (days 1, 3, 7, and 14; Figure 2B ). Although comparing with the sham limbs, the change in miR-15b-5p expression on day 21 after surgery was not statistically significant, a trend toward decreased expression was observed. Accordingly, circulating miR-15b-5p expression in plasma of mice after femoral artery ligation was obviously downregulated compared with that in the sham mice (days 1, 3, 7; Figure 2C ). To determine which cell expresses miR-15b-5p in adductors, the cellular localization in sham-and ligature-treated mice was studied by in situ hybridization with a digoxigenin-labeled miR-15b-5p oligonucleotide probe on paraffin sections of adductors. As shown in Figure 2D , continuous adjacent slices were stained with CD31 to visualize vessels and discriminate the ECs. In the same view of each group, the miR-15b-5p was highly expressed in vascular EC layer of sham-treated adductors in mice; however, a diminished miR-15b-5p expression was detected in EC layer of collaterals on day 7 after femoral ligation, which was in accordance with low expression of circulating miR-15b-5p after ischemic injury in mice. These results suggested that circulating miR-15b-5p was mainly derived from ECs and was reduced because of a decreased expression in EC layer of collaterals.
MiR-15b-5p Inhibits Arteriogenesis and Angiogenesis in Mice After Hindlimb Ischemia
To determine the role of miR-15b-5p in collateral growth in vivo, gain-of-function studies by locally injecting with agomiR-15b into adductors after ischemia surgery were performed. Transduction of adductors with agomiR-15b resulted in an obviously increased miR-15b-5p expression compared with that with agomiR-negative control (agomiR-NC; 12.3-fold; Figure 3A ). As shown in Figure 3B , continuous blood flow recovery during the entire observation period and a maximum recovery of 95% on day 21 were observed in agomiR-NC-treated mice. In contrast, the agomiR-15b group displayed defective perfusion recovery, and the blood flow recovery in the hindlimbs was attenuated after day 7 (day 7, 38.3±4.1% versus 50.9±6.6%; P<0.05; day 14, 37.5±5.5% versus 71.8±5.3%; P<0.01; day 21, 56.5±4.0% versus 92.2±2.2%; P<0.01).
Hematoxylin and eosin staining and immunohistochemistry of SMA (anti-smooth muscle antibody) and Ki67 (a proliferation marker) in the adductors were used to further determine the effects of miR-15b-5p on arteriogenesis ( Figure 3C and 3D) . On day 14 after femoral ligation, the numbers of collaterals in agomiR-15b-treated mice were found to be lower than those in agomiR-NC group (1.8±0.8 versus 3.8±0.8; P<0.01). In addition, the mean artery area 13 was lower in agomiR-15b-treated mice (1969.5±512 versus 3206.7±206.71 μm2; P<0.05). We next assayed cell proliferation in and around the collaterals by Ki67 staining.
14 agomiR-15b-treated mice exhibited lower Ki67 expression compared with the negative control group (5.9±5.6 versus 26.0±9.0; P<0.01). To evaluate whether in vivo EC proliferation was instrumental to the arteriogenesis impaired by miR-15b-5p, we performed double staining of Ki67 and CD31 in adductor muscles 3 days after surgery. As shown in Figure 3E , adductor muscles injected with agomiR-15b presented a significant reduction in Ki67-positive ECs compared with the those with agomiR-NC (14.2±4.9% versus 45.8±7.5%; P<0.01). These results suggested that miR-15b-5p markedly inhibited arteriogenesis in mice after hindlimb ischemia.
To determine whether miR-15b-5p could impact ischemiamediated angiogenesis in the lower limb, the ischemic gastrocnemius of sham-, ligature-, agomiR-15b-and agomiR-NC-treated mice euthanized on 21 days after femoral artery ligation were stained for CD31 to visualize capillary formation. As shown . miR-15b-5p impairs arteriogenesis in a murine hindlimb ischemic model. A, The expression of miR-15b-5p in adductor muscles after agomiR-15b-5p or agomiR-NC injection in the murine hindlimb after femoral artery ligation. B, Representative laser speckle perfusion images and statistical analysis of the ratios of left to right (L/R) hindlimb blood perfusion among ligature-, agomiR-NC-, and agomiR15b-5p-treated mice at various time points after femoral artery ligation. C, Hematoxylin and eosin (HE) staining, immunohistochemistry of SMA and Ki67 in cross-sections of the adductor muscles collected from sham-, ligature-, agomiR-NC-, and agomiR-15b-5p-treated adductor muscles 14 days after femoral artery ligation. D, Quantification of collateral lumen numbers measured by HE staining, mean artery lumen areas assayed by SMA staining, and proliferating cells measured by Ki67 staining in sham-, ligature-, agomiR-NC-, and agomiR-15b-5p-treated mice 14 days after ligation. E, Bar graph and representative immunofluorescence staining of CD31 (red), Ki67 (green), and DAPI (blue) in sham-, ligature-, negative control-, and agomiR-15b-5p-treated mice 3 days after femoral artery ligation. The ratio of Ki67 positive cells to total endothelial cell (EC) number in each field was compared. Arrows show some of proliferating endothelial cells. Scale bar =50 μm. n=8 mice in each experimental group; multi-time points vs pre or sham, agomiR-15b-5p vs agomiR-NC, *P<0.05, **P<0.01; ligature vs sham, #P<0.05, ##P<0.01. NC indicates negative control.
in Figure IVA in the online-only Data Supplement, a decrease in the number of capillaries was observed in the left ischemic gastrocnemius treated with agomiR-15b compared with mice treated with agomiR-NC (7±2.6 versus 33±4; P<0.01).
MiR-15b-5p Plays a Key Role in EC Migration and Proliferation
Although miR-15b-5p is mainly expressed in ECs and impacted EC proliferation in vivo, we further studied the effect of miR-15b-5p treatment on human umbilical vein ECs (HUVECs). After being treated with VEGF (1, 3, or 10 ng/ mL) and cultured for 3, 6, 12, or 24 hours, HUVECs exhibited inhibited miR-15b-5p expression in a dose-and time-dependent manner ( Figure 4A and 4B) . Moreover, a higher concentration of VEGF (30 ng/mL) did not cause dose-dependent miR-15b-5p inhibition. Based on these findings and previous studies, we selected a dose of 10 ng/mL of VEGF for the subsequent experiments. To investigate whether VEGF affects miR-15b-5p secretion from HUVECs, cell supernatant was collected to detect the miR-15b-5p expression by quantitative reverse transcription polymerase chain reaction after 24-hour stimulation with basal and VEGF (10 ng/mL). A diminished miR-15b-5p expression was detected in HUVECs supernatant under VEGF stimulation compared with basal stimulation (P<0.01; Figure III in the online-only Data Supplement).
To determine whether miR-15b-5p is involved in EC migration and proliferation, gain-and loss-of-function studies were performed. As shown in Figure 4C and 4E, transfection of HUVECs with agomiR-15b significantly inhibited both migration, as determined by the scratch-wound healing assay, and proliferation, as revealed by CCK8 (cell counting kit 8; P<0.05 and P<0.05, respectively). In contrast, antagomiR-15b significantly increased the migration and proliferation of HUVECs (P<0.01 and P<0.01, respectively). Accordingly, agomiR-15b transfection significantly inhibited VEGF-induced HUVECs migration and proliferation (P<0.01 and P<0.01, respectively). Furthermore, downregulation of miR-15b-5p expression by antagomiR-15b enhanced the migration and proliferation of HUVECs in response to VEGF (P<0.01 and P<0.01, respectively; Figure 4D and 4F).
Identification of AKT3 as a Downstream Target of miR-15b-5p In Vitro and In Vivo
As shown in Figure 5A , 2 highly conserved putative target sites of miR-15b-5p among human, rat, and mouse species for 24 h. B, miR-15b-5p expression in HUVECs treated with VEGF (10 ng/mL) at different time points. C and D, The effects of miR-15b-5p on HUVEC migration determined by the scratch-wound healing assay with agomiR-15b-5p (50 pmol/L), antagomiR-15b-5p (100 pmol/L), or negative controls under basal (C) or VEGF (10 ng/mL) stimulation (D). E and F, The effects of miR-15b-5p on HUVEC proliferation determined by the CCK8 assay with agomiR-15b-5p (50 pmol/L), antagomiR15b-5p (100 pmol/L), or negative controls under basal (E) or VEGF (10 ng/ mL) stimulation (F). *P<0.05, **P<0.01 for agomiR-15b-5p vs agomiR-NC (C and E), VEGF+agomiR-15b-5p vs VEGF+agomiR-NC (D and F) ; #P<0.05, ##P<0.01 antagomiR-15b-5p vs antagomiR-NC (C and E), VEGF+antagomiR-15b-5p vs VEGF+antagomiR-NC (D and F). Each experiment was repeated >3 times. NC indicates negative control. Figure 5 . miR-15b-5p targets AKT3 (protein kinase B-3) in vitro and in vivo. A, Two highly conserved putative target sites of miR-15b-5p in AKT3 mRNA 3′UTR, predicted by target scan analysis. B, human umbilical vein endothelial cells (HUVECs) transduced with agomiR15b-5p (50 pmol/L) or agomiR-NC were cotransfected with the luciferase reporter carrying WT1-AKT3-3′UTR, MUT1 AKT3-3′UTR, WT2-AKT3-3′UTR, and MUT2-AKT3-3′UTR, respectively. The luciferase activities were measured by a luminometer. C, The effects of miR15b-5p on AKT3 mRNA expression in HUVECs transfected with agomiR-15b-5p (50 pmol/L), antagomiR-15b-5p (100 pmol/L), or negative controls (NC). D and E, The effects of miR-15b-5p on AKT3 protein expression in HUVECs transfected with agomiR-15b-5p (50 pmol/L), antagomiR-15b-5p (100 pmol/L), or negative controls under basal (D) or vascular endothelial growth factor (VEGF; 10 ng/mL) stimulation (E). F, Representative immunofluorescence staining and quantification of α-SMA and AKT3 in sham-, ligature-, agomiR-15b-5p-, and negative control-treated mice 14 days after femoral artery ligation. The ratio of positive cells to total cell number in each collateral was compared. *P<0.05, **P<0.01 for agomiR-15b-5p+WT1-AKT3-3′UTR vs agomiR-NC+WT1-AKT3-3′UTR, agomiR-15b-5p vs agomiR-NC, VEGF+agomiR-15b-5p vs VEGF+agomiR-NC; #P<0.05, ##P<0.01 for antagomiR-15b-5p vs antagomiR-NC. VEGF+antagomiR-15b-5p vs VEGF+antagomiR-NC. Ligature vs sham. Each cellular experiment was repeated 3 times. n=8 mice in each group. NC indicates negative control.
in the AKT3 mRNA 3′UTR were predicted as the downstream targets of miR-15b-5p by computational analysis using Targetscan software.
Overexpression of miR-15b-5p by agomiR-15b significantly repressed the activity of luciferase fused with WT1-3′UTR (wild type1-3′ untranslated region) of AKT3 (P<0.01) but exerted no effect on luciferase activity when the miR-15b-5p binding sites in the 3′UTR [mutation1-3′ untranslated region] of AKT3 were mutated (MUT1-3′UTR of AKT3). However, overexpression of miR-15b-5p had no inhibitory effect on the activity of luciferase fused with either WT2-3′UTR or MUT2-3′UTR of AKT3 (Figure 5B ), suggesting that miR-15b-5p can directly bind to the 3′UTR of WT1-AKT3 and regulate its expression.
To further verify that AKT3 is a functional target gene of miR-15b-5p in collateral growth, we transfected HUVECs with agomiR-15b, antagomiR-15b, or negative controls. As shown in Figure 5C , overexpression or inhibition of miR-15b-5p reduced and promoted mRNA levels of AKT3 in HUVECs, respectively (P<0.05). Western blot analysis revealed that overexpressing miR-15b-5p suppressed AKT3 protein expression levels in HUVECs and that knocking down miR-15b-5p promoted AKT3 expression under both basal (P<0.05; Figure 5D ) and VEGF-stimulated conditions (P<0.05; Figure 5E ).
Considering that the binding site of miR-15b-5p in the AKT3 3′UTR is highly conserved among different species, the hindlimb ischemia mice were transduced with agomiR15b and a negative control ( Figure 5F ). On day 14 after femoral artery ligation, the numbers of AKT3-positive cells in collateral vessels were significantly greater in the ligaturetreated adductors compared with the adductors in the sham group (44.0±5.5% versus 2.5±2.2%). Moreover, the expression of AKT3 in collateral vessels was markedly inhibited in agomiR-15b-treated adductors compared with that in the agomiR-NC-treated group (11.9±2.8% versus 52.7±8.4%).
With the identification of AKT3 as an authentic miR-15b-5p downstream target during ECs activation, we further explored the functional importance of AKT3 in miR-15b-5p-mediated HUVECs proliferation. Rescue studies by CCK8 assays showed that miR-15b-5p and AKT3 overexpression alone in VEGF-induced HUVECs significantly decreased and increased These supporting data suggested that AKT3 acted as the downstream target of miR-15b-5p in its mediation of EC activation.
AKT3 Promotes EC Migration and Proliferation In Vitro
To further verify the functional significance of AKT3 in ECs, a loss-of-function study was performed using AKT3 siRNA.
The results indicated that AKT3 knockdown by AKT3 siRNA transfection ( Figure 6A ) markedly inhibited the migration (P<0.01 and P<0.01, respectively) and proliferation (P<0.05 and P<0.05, respectively) of HUVECs under both basal and VEGF-treated conditions ( Figure 6B and 6C) . To further validate the downstream molecule of AKT3, endothelial nitric oxide synthase (eNOS) protein expression was determined. As shown in Figure 6D , eNOS protein expression in HUVECs was significantly inhibited by AKT3-siRNA. Moreover, AKT3 depletion also attenuated the eNOS protein expression induced by VEGF. These data indicated that AKT3 plays a key role in ECs migration and proliferation.
Arteriogenesis Is Impaired in Mice Lacking AKT3
AKT3 mRNA expression was downregulated in the adductors after ischemia surgery by local injection of Chol-AKT3 siRNA ( Figure 7A ). To investigate whether AKT3 affects EC proliferation in the early phase of arteriogenesis, Figure 7B demonstrated the amount of staining for Ki67 cell proliferation marker in day 3 adductors after ischemia surgery treated with Chol-CTRL-siRNA or Chol-AKT3-siRNA, comparing with Chol-CTRL-siRNA-treated groups, a diminished proliferation ratio of ECs was detected in Chol-AKT3-siRNA-treated groups. (16.4±4.0% versus 45.4±8.4%; P<0.01). Laser speckle contrast imaging revealed that the blood recovery was significantly inhibited from day 14 (46.3±8.2% versus 65.7±5.5%; P<0.05) to day 21 (54.5±6.1% versus 93.7±4.01%; P<0.01) in the Chol-AKT3 siRNA-treated groups compared with that in the Chol-CTRL siRNA-treated group ( Figure 7C ).
To test whether AKT3 is required in collateral growth, we examined the adductor 14 days after femoral artery ligation. Similarly, the induction of arteriogenesis in the adductor was defective in Chol-AKT3 siRNA-treated mice compared with that in the Chol-CTRL siRNA-treated mice, which was reflected by significantly different lumen numbers (2.0±1.2 versus 4.8±1.3; P<0.01), artery area (1794±416.3 versus 3443±899 μm 2 ; P<0.05), and Ki67 expression (6.4±4.3 versus 27.1±13.6; P<0.01; Figure 7D and 7E).
Next, we investigate the effect of AKT3 on angiogenesis in vivo; our data showed that injection with Chol-AKT3-siRNA in gastrocnemius impaired the number of capillaries on 21 days after femoral artery ligation compared with Chol-CTRL-siRNA treatment (11.7±2.5 versus 34.3±3.5; P<0.01; Figure IVB in the online-only Data Supplement).
Discussion
In the past few years, increasing evidence has documented an important regulatory function of miRNAs in coronary collateral development. MiR-145 restores the contractile vascular smooth muscle phenotype and coronary collateral growth in metabolic syndrome (JCR rats). 9 Furthermore, the miR-132/212 cluster promotes arteriogenesis by modulating Ras-MAPK signaling by directly targeting its inhibitors, Rasa1 and Spred1. 15 More recently, a study in Japan identified that circulating miR423-5p, miR30d, miR10b, and miR126 are upregulated in the plasma of chronic total occlusion patients with low coronary collateral artery capacity and also revealed that these miRNAs can be used as circulating biomarkers to discriminate between patients with insufficient collateral arteries and patients with sufficient collateral artery capacity. 10 Coronary collaterals act as a natural bypass mechanism to maintain blood supply to downstream tissue even when major coronary arteries become blocked. Therefore, the inclusion criterion in the present study was severe coronary artery disease, defined as severe triple coronary artery disease or left main coronary artery disease with luminal diameter stenosis ≥90%. What's more, considering several coexisting parameters might affect the diagnostic ability of miRNAs in the general population, we exclude the patients with diabetes mellitus, infection, acute myocardial infarction, and other influence factors. The diversity of inclusion and exclusion criteria may explain the differences in miRNA profiles between previous reports and our study. In the present study, we used high-throughput sequencing in training cohort and performed further validation by quantitative reverse transcription polymerase chain reaction in an independent cohort to detect significantly greater miR-15b-5p and miR-126-3p in the plasma of patients with poor CCC compared with those with good CCC. In several previous studies, miR-126 was identified as having critical effects on arteriogenesis and angiogenesis. 10, 11 Therefore, we further confirmed the key role of miR-15b-5p in collateral artery formation. To determine the biomarker role of plasma miR-15b-5p, we also detected miR-15b expression in plasma of healthy controls, and a gradually decreasing trend was observed in healthy controls, poor CCC group, and good CCC group. Receiver operating characteristic analyses for the diagnostic power of miR-15b presented an AUC of 0.69 with 50% sensitivity and 90% specificity in differentiating patients with good CCC from those with poor CCC, AUC of 0.88 with 83% sensitivity and 94% specificity in differentiating patients with good CCC from healthy controls, and AUC of 0.76 with 55% sensitivity and 94% specificity in differentiating patients with poor CCC from healthy controls. These results suggested that plasma miR-15b may be a valuable biomarker of CCC. Although we adopted an independent validation cohort in our study, because of highly selective population of patients, the number of cases is relatively insufficient, which may raise some statistical issues regarding logistic regression and the interpretation of C statistics. A larger, randomized, multicenter, controlled trial will be beneficial to illuminate the relationship between circulating miR-15b-5p and CCC.
The functional significance of miR-15b-5p in human diseases has only recently been explored. Accumulating evidence suggests that miR-15b-5p is critically involved in cell growth and angiogenesis in vitro and in zebra fish model. 8 However, the role of miR-15b-5p in arteriogenesis and its molecular mechanisms remain elusive. Because it would be against the ethics to obtain the suspected cells or tissues (collateral arteries) from patients, we compared miR-15b expression in adductors between sham-and ligature-treated mice to explore the source of circulating miR-15b in murine hindlimb model. We found that miR-15b-5p was specifically expressed in vascular ECs in sham group and was significantly depressed in ECs layer of collaterals in ligation group. Interestingly, HUVECs secreted a diminished miR-15b-5p after VEGF stimulation in vitro; these data suggested that EC was the main source of circulating miR-15b-5p. Furthermore, overexpression of miR15b-5p by agomiR-15b remarkably inhibited arteriogenesis and angiogenesis in mice after hindlimb ischemia, as shown by hematoxylin and eosin staining and immunohistochemistry with SMA, Ki67, and CD31. Taken together, the human and animal data showed that miR-15b-5p plays a direct role in collateral vessel growth. What's more, loss-and gain-function studies demonstrated that miR-15b-5p regulates EC proliferation and migration with or without VEGF stimulation. According to our clinical research, miR-15b can act as biomarker for discriminating patients with good or poor CCC. However, given the multifactorial inhibitory roles of miR15b-5p in arteriogenesis and angiogenesis, thus, miR-15b may not be used as a proper biomarker to discriminate the arteriogenesis and angiogenesis.
AKT3 belongs to the AKT family and has 3 closely related isoforms, AKT1, AKT2, and AKT3, which are the main effectors of a well-established proangiogenic pathway (VEGF/ PI3K/PKB; AKT). In particular, the PI3K/AKT pathway is important in regulating cell survival, cell motility, and nitric oxide production. 16 The role of AKT3 in angiogenesis has been implicated in several studies. One study showed that AKT3 is involved in the regulation of RCAS1 (receptor-binding cancer antigen expressed on SiSo cells, a tumor marker) and VEGF secretion in ovarian cancer cells. 17 Another study demonstrated that restoration of AKT3 expression could prevent the impaired angiogenesis induced by miR-22 in endothelial progenitor cells, suggesting that AKT3 plays a functional role in promoting angiogenesis. 18 In the present study, we demonstrate, for the first time, that AKT3 is the target of miR-15b-5p and plays a key role in arteriogenesis both in vivo and in vitro. First, 2 highly conserved putative target sites of miR-15b-5p among human, rat, and mouse species in the AKT3 mRNA 3′UTR were predicted by computational analysis. Therefore, we confirmed that miR-15b-5p can directly bind to the 3′UTR of WT1-AKT3 by applying luciferase reporter assay. In addition, AKT3 protein expression levels were adversely regulated by miR-15b-5p with or without VEGF stimulation. Overexpression of miR-15b-5p markedly inhibited arteriogenesis, which was accompanied by decreased expression of AKT3 in vivo. Second, we also conformed that AKT3-siRNA inhibited arteriogenesis in vivo and in vitro. Third, we found that the effects of antagomiR-15b or agomiR-15b on ECs' proliferation were reversed by AKT3 siRNA or AKT3 overexpression with pCMV-AKT3, respectively.
Activation of eNOS signaling plays a key role in the remodeling of the preexisting collaterals by biomechanical factors, including shear stress and VEGF. 1 In the present study, eNOS protein expression in AKT3-siRNA-treated ECs significantly decreased under both basal and VEGF-stimulated conditions, indicating that eNOS is the downstream molecule of AKT3.
In summary, for the first time to our knowledge, we identified that circulating miR-15b-5p is substantially downregulated in coronary heart disease patients with sufficient collateral artery function and suitable for discriminating between patients with well versus poorly developed collateral arteries. We demonstrated that miR-15b-5p specifically expresses in the vascular ECs. Moreover, we found that miR-15b-5p is a critical regulator of human EC proliferation and migration by targeting the AKT3/eNOS pathway, which controlled collateral artery formation in a murine hindlimb ischemia model. Interestingly, AKT3 deficiency notably inhibited arteriogenesis and blood recovery. It was needed to point out that C57BL/6 mice are known to develop good collaterals, whereas Balb/c mice do not, 19 and it will be absolutely helpful for exploring the role of miR-15b using different mouse strains in future work. Above all, modulation of AKT3 expression by miR-15b-5p may have potential as a therapeutic target for the treatment of collateral artery formation.
